Method for classifying cancer patients into appropriate hepatocellular carcinoma treatment groups and compounds for treating the patient
US12276664B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Nov 29, 2018 |
| Grant date | Apr 15, 2025 |
| Priority date | — |
| Expiry date | Sep 28, 2040 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
A method for the prognosis of response to treatment for a patient suffering from cancer, the method comprising: measuring the expression of at least one immune marker in a leukocyte sample taken from the patient with cancer; classifying the patient sample into (i) sustainable responders (SR) to selective internal radiation therapy (SIRT) or (ii) transient/non-responders (TR/NR) to (SIRT) based on expression of the at least one immune marker in relation to a predetermined value and treating sustainable responders (SR) to SIRT or SIRT or a composition comprising SIRT and an immunotherapy. In a preferred embodiment, the method is for the prognosis of response to treatment of a Hepatocellular carcinoma (HCC) patient comprising detecting the co-expression of PD-1 or Tim-3 with CCR5; or expression of PD-1, Tim-3, CXCR6, or combinations thereof in a leukocyte sample taken from the patient.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.